![](https://d2jx2rerrg6sh3.cloudfront.net/image-handler/picture/2014/7/Antibody-620x480.jpg)
MD Anderson and Summit Therapeutics partner to accelerate ivonescimab development
The University of Texas MD Anderson Cancer Center and Summit Therapeutics, Inc. today announced a strategic five-year collaboration agreement for the purpose of accelerating the development of ivonescimab. Leveraging MD Anderson's clinical …